Ribo et Boehringer Ingelheim font progresser leur programme siRNA pour la stéatohépatite associée à un dysfonctionnement métabolique (MASH)

PartnershipPositive

AI Analysis

Summary

Ribo and Boehringer Ingelheim announced the achievement of a third key milestone in their siRNA program development for metabolic dysfunction-associated steatohepatitis (MASH).

Outcome Details

Collaboration milestone achieved - third key stage completed

Importance:6/10

Sentiment:

0.60

partnershipsiRNAMASHmetabolic diseasecollaboration milestone

Related Companies

$6938

Read the original article

Published by PR Newswire Pharma on May 7, 2026 5:36 AM

Read Original